Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03804060
Other study ID # EDC-3599
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 23, 2019
Est. completion date May 1, 2024

Study information

Verified date May 2024
Source ZOLL Circulation, Inc., USA
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to determine the feasibility and safety of achieving rapid hypothermia with the Proteus Intravascular Temperature Management (IVTM) system for patients experiencing acute ischemic stroke due to a large vessel occlusion.


Recruitment information / eligibility

Status Completed
Enrollment 90
Est. completion date May 1, 2024
Est. primary completion date May 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility All Inclusion Criteria must be answered YES for Patient to be eligible. 1. Age =18 and =85; 2. Signs and symptoms consistent with an acute ischemic stroke with anterior circulation large vessel occlusion (M1 MCA, carotid-terminus occlusion, Tandem occlusion allowed (Extracranial ICA+carotid T or M1 MCA)) as determined by CT imaging; (i.e., hyperdense sign on non-contrast CT or CT angiogram); 3. Ability to perform arterial puncture within 24 hours from symptom onset or LKN; 4. ASPECTS score of 6-10 on non-contrast CT of the brain if under 80 years; ASPECTS 9-10 if age 80-85; 5. For transfer patients with anticipated arterial puncture greater than 6 hours from symptom onset or LKN, qualifying imaging must be performed within 2 hours prior to enrolling hospital arrival; or with a newly obtained non-contrast CT scan if this time is exceeded 6. Candidate for endovascular thrombectomy therapy in accordance with best practices per AHA standard stroke guidelines meeting all labeling requirements for EVT in the trial; 7. No contraindications to general anesthesia, conscious sedation or allergies to any components associated with the anticipated diagnostic or treatment procedures that cannot be treated; 8. A pre-stroke modified Rankin Score (mRS) of 0 or 1 (Appendix 4); 9. Baseline CT scan shows no hemorrhage; 10. NIHSS greater than or equal to 8 (Appendix 3); 11. Patient is capable of complying with study procedures and agrees to complete all required study procedures, study visits and associated activities; 12. Legally authorized representative must be able to understand and give written informed consent. Patient will assent if capable. Patient may be re-consented once it is established that there is no memory loss or cognitive impairment. 5.2 Exclusion Criteria In order to be eligible for participation, patients must meet all Inclusion and Exclusion Criteria. Inclusion Criteria All Inclusion Criteria must be answered YES for Patient to be eligible. 1. Age =18 and =85; 2. Signs and symptoms consistent with an acute ischemic stroke with anterior circulation large vessel occlusion (M1 MCA, carotid-terminus occlusion, Tandem occlusion allowed (Extracranial ICA+carotid T or M1 MCA)) as determined by CT imaging; (i.e., hyper dense sign on non-contrast CT or CT angiogram); 3. Ability to perform arterial puncture within 24 hours from symptom onset or LKN; 4. ASPECT score of 6-10 on non-contrast CT of the brain if under 80 years; ASPECTS 9-10 if age 80-85; 5. For transfer patients with anticipated arterial puncture greater than 6 hours from symptom onset or LKN, qualifying imaging must be performed within 2 hours prior to enrolling hospital arrival or with a newly obtained non-contrast CT scan if this time is exceeded; 6. Candidate for endovascular thrombectomy therapy in accordance with best practices per AHA standard stroke guidelines meeting all labeling requirements for EVT in the trial; 7. No contraindications to general anesthesia, conscious sedation or allergies to any components associated with the anticipated diagnostic or treatment procedures that cannot be treated; 8. A pre-stroke mRS of 0 or 1 (Appendix 4); 9. Baseline CT scan shows no hemorrhage; 10. NIHSS greater than or equal to 8 (Appendix 3); 11. Patient is capable of complying with study procedures and agrees to complete all required study procedures, study visits and associated activities; 12. Legally authorized representative must be able to understand and give written informed consent. Patient will assent if capable. Patient may be re-consented once it is established that there is no memory loss or cognitive impairment. Exclusion Criteria All Exclusion Criteria must be answered NO to be eligible. 1. Patient arrives to the enrolling hospital intubated 2. Female patients of childbearing potential who are known to be or may be pregnant; 3. The patient has a known history of bleeding diathesis, coagulopathy, cryoglobulinemia, sickle cell anemia, will refuse blood transfusions or contraindication to heparin; history of genetically confirmed hypercoagulable syndrome 4. The patient has a height of < 1.5 meters (4 feet 11 inches); 5. Use of warfarin with INR > 1.7; 6. Blood clinical chemistry potassium (K+) < 2.7; 7. History of severe dementia and currently taking medication for cognitive impairment or behavior disorder; 8. End stage renal disease on hemodialysis; 9. Known presence of an IVC filter; 10. Contrast dye allergy with history of anaphylaxis, known serious sensitivity to contrast agents or any condition in which angiography is contraindicated; 11. Known to have contraindications to radiological imaging; 12. Known allergy to meperidine or buspar or dexmedetomidine; 13. Sustained hypertension (SBP > 185 or DBP > 110 unable to be treated with a continuous infusion, e.g., nicardipine); 14. Baseline CT/MR showing evidence of arterial vasculitis or dissection; 15. Baseline CT/MR evidence of multiple vascular territory acute stroke; 16. Excessive tortuosity of cervical vessels; 17. Intracranial stent in area that may impact Recanalization; 18. Presence of Pulmonary embolism, ilio-femoral or deep vein thrombosis 19. Presence of clinical signs of sepsis 20. Ongoing or spontaneous atrial fibrillation indicating severe peripheral vascular disease, aortic disease, or proximal cerebrovascular disease that in the opinion of the investigator precludes access or safe endovascular treatment 21. Presence of any other serious comorbidity that would be likely to impact life expectancy to less than 6 months or limit Patient cooperation or study compliance 22. Concurrent participation in an investigational clinical study (excluding registries) that has not completed the follow-up period or planned participation in another study within the next 3 months; 23. Patient has any other condition(s) or circumstance(s) that, in the judgement of the investigator, might interfere with or impact the collection of high quality data, or with the completion of follow up requirements within the study windows. 24. Patient has active or symptomatic COVID-19 25. Patients without a legally authorized representative to sign the consent form will be excluded.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Thermogard XP3
Cooling with the ZOLL® Circulation catheter and the ZOLL® Intravascular Temperature Management system to initiate and maintain hypothermia for 6 hours as an adjunct to endovascular Recanalization.
Procedure:
Recanalization only
Standard of Care for recanalization

Locations

Country Name City State
United States University of Maryland Medical Center Baltimore Maryland
United States University of Chicago Medical Center Chicago Illinois
United States Henry Ford Detroit Michigan
United States The Queen's Medical Center Honolulu Hawaii
United States WellStar Kennestone Regional Medical Center Marietta Georgia
United States University of Pittsburgh Medical Center Pittsburgh Pennsylvania
United States Mercy Health Toledo Ohio
United States ProMedica Toledo Hospital Toledo Ohio

Sponsors (1)

Lead Sponsor Collaborator
ZOLL Circulation, Inc., USA

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Test Arm patients achieving target temperature Percentage of Test Arm patients achieving target temperature < 34 ºC within 1 hour of arterial puncture for thrombectomy 1 hour after thrombectomy
Primary Mean door-to-Recanalization time door-to-Recanalization time perioperative
Primary Rate of hemorrhagic conversion in each arm within 36 hours of Recanalization Rate of hemorrhagic conversion 36 hours
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Recruiting NCT05518305 - Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
Recruiting NCT06029959 - Stroke and CPAP Outcome Study 3 N/A
Recruiting NCT03728738 - Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke Phase 3
Terminated NCT03396419 - IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
Recruiting NCT05065216 - Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) Phase 2/Phase 3
Recruiting NCT04897334 - Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke N/A
Not yet recruiting NCT06462599 - Osteopontin Gene Polymorphism in Stroke Patients in Egypt
Not yet recruiting NCT06032819 - Differentiating Between Brain Hemorrhage and Contrast
Not yet recruiting NCT06026696 - Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
Recruiting NCT02910180 - Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
Withdrawn NCT01866189 - Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke N/A
Completed NCT02922452 - A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects Phase 1
Completed NCT03554642 - Walkbot Robotic Training for Improvement in Gait Phase 3
Recruiting NCT03041753 - Reperfusion Injury After Stroke Study N/A
Completed NCT02549846 - AdminiStration of Statin On Acute Ischemic stRoke patienT Trial Phase 4
Completed NCT01678534 - Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial Phase 2
Completed NCT02610803 - Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke N/A